Inventiva S.A.
IVA
Rangering i aksjer
#10161
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Aksjekurs
$3.48
Markedsverdi
$821.04M
Endring (1 dag)
-0.64%
Endring (1 år)
-5.88%
Land
FR
Handel Inventiva S.A. (IVA)
Kategori
Healthcare
Aksjeprishistorikk for Inventiva S.A. (IVA)
Høyeste sluttskurs: $3.42 den 2026-10-01
Laveste sluttskurs: $11.50 den 2021-08-01
Laveste sluttskurs: $11.50 den 2021-08-01
Aksjeprishistorikk for Inventiva S.A. fra 2021 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 11.32% |
| 2025 | 81.18% |
| 2024 | -45.73% |
| 2023 | -3.30% |
| 2022 | -66.26% |
| 2021 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.98 | 25.92% |
US
|
|
| $224.77 | 737.11% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.75 | 7.69% |
NL
|
